PlainPharmaWatch

CMS Open Payments · Program Year 2024

Tonix Medicines, Inc.

Tonix Medicines, Inc. reported $63,252.85 across General Payments, Research, and Ownership to 1,107 physicians and teaching hospitals across 1,107 transactions.

$63.3K
All-tracks total
1,107
Transactions
1,107
Recipients
+$22.0K
General Payments vs PY2023

Tonix Medicines, Inc. reported $63,252.85 across all CMS Open Payments tracks (General + Research + Ownership) to 1,107 physicians and teaching hospitals in Program Year 2024 - ranking #1288 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $63,252.85, averaging $57.14 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer tonix-medicines-inc Tonix Medicines, Inc.

$63.3K · #1288/1,925 · 0.0% industry · PY2024

  • TOT $63.3K
  • RANK #1288
  • SHARE 0.0%
  • TXN 1,107
  • RCP 1,107
  • CAT 2
  • GEN $63.3K
  • ΔGEN +$22.0K
  • TOP1 7.3%
  • PY 2024

Nearest volume peer: Medela LLC ($63.1K)

Tonix Medicines, Inc. (this)$63.3KMedela LLC$63.1KDentium USA$63.0KMIS Implants Technologies, I…$62.9KCardinal Health Inc$62.6K
All-tracks payment totals near Tonix Medicines, Inc. (CMS Open Payments PY2024)

Tonix Medicines, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Tonix Medicines, Inc.'s CMS-reported General Payments increased by $22.0K (+53.4%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: TONIX MEDICINES, INC.PY2024: Tonix Medicines, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$41.2KPY2024$63.3K
PY2023
$41,223.47
PY2024
$63,252.85

What the Data Shows for Tonix Medicines, Inc.

$63,252.85: that is what Tonix Medicines, Inc. reported in payments to 1,107 physicians and teaching hospitals during Program Year 2024, spread across 1,107 transactions ($57.14 per transaction, $57.14 per recipient). The company sits at rank #1288 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $36.5K, accounting for 57.7% of this company's General Payments and 38 transactions.

General Payment Breakdown by Type

Tonix Medicines, Inc. made 2 types of general payments. "Honoraria" is the largest category at $36.5K, 57.7% of General Payments.

How Tonix Medicines, Inc. divides its payments

General-payment categories, ordered by reported total

1. Honoraria$36.5K2. Food and Beverage$26.8K
Payment Type Amount Transactions
Honoraria $36.5K 38
Food and Beverage $26.8K 1,069

Recipient Concentration in General Payments

The five largest recipient relationships account for $12,872.81 (20.4%) of $63,252.85 in this company's General Payments records across 284 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Tonix Medicines, Inc.

The five named recipients with the highest reported General Payments from this company

Stewart Tepper$4.6KLaszlo Mechtler$2.5KGeorge Nissan$2.3KStephanie Nahas-Geiger$1.8KAndrew Blumenfeld$1.7K
  1. 1

    Stewart Tepper

    $4,586.11 across 7 reported transactions

  2. 2

    Laszlo Mechtler

    $2,510.00 across 46 reported transactions

  3. 3

    George Nissan

    $2,256.14 across 12 reported transactions

  4. 4

    Stephanie Nahas-Geiger

    $1,777.95 across 4 reported transactions

  5. 5

    Andrew Blumenfeld

    $1,742.61 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Tonix Medicines, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Tonix Medicines, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Tonix Medicines, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Tonix Medicines, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.